Brincidofovir fails to improve survival in adenovirus study

Chimerix Inc. (NASDAQ:CMRX) slipped $0.21 to $4.91 on Monday after disclosing with its 1Q16 financial results that brincidofovir ( CMX001) did not meaningfully improve overall survival at week 24 compared to historical controls in the open-label Phase III AdVise study to treat adenovirus infection. The company will not seek brincidofovir's approval based on the AdVise data, and instead intends to conduct a comparative study.

In 3Q16, the company plans to disclose final 36-week mortality data from AdVise and give an update on its plans for brincidofovir. The company said Monday that the study's primary endpoint is all-cause mortality at week 36. ...